MeSH term
Frequency | Condition_Probility | Humans | 156 | 0.0 |
Child | 5 | 0.0 |
Chromosomes, Human, Pair 17 | 4 | 1.0 |
Chromosomes, Human, Pair 19 | 5 | 2.0 |
DNA-Binding Proteins/*genetics | 3 | 0.0 |
Female | 31 | 0.0 |
Research Support, Non-U.S. Gov't | 109 | 0.0 |
Translocation, Genetic | 5 | 0.0 |
DNA Damage/*drug effects | 2 | 4.0 |
Drug Synergism | 4 | 0.0 |
Iron/*metabolism | 3 | 2.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Animals | 65 | 0.0 |
Base Sequence | 30 | 0.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
DNA Primers | 6 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Mice | 37 | 0.0 |
Molecular Sequence Data | 43 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Tumor Cells, Cultured | 28 | 0.0 |
Adsorption | 2 | 1.0 |
Antiviral Agents/*pharmacology | 2 | 1.0 |
Cattle | 20 | 0.0 |
Cell Line | 22 | 0.0 |
In Vitro | 7 | 0.0 |
Lactoferrin/*pharmacology | 7 | 30.0 |
Cell Survival/drug effects | 3 | 0.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Dose-Response Relationship, Drug | 9 | 0.0 |
Flow Cytometry | 3 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 37 | 0.0 |
Comparative Study | 16 | 0.0 |
Male | 35 | 0.0 |
Mice, Inbred CBA | 2 | 0.0 |
Amino Acid Sequence | 31 | 0.0 |
Cells, Cultured | 22 | 0.0 |
Phosphorylation | 5 | 0.0 |
Structure-Activity Relationship | 5 | 0.0 |
Trans-Activation (Genetics) | 6 | 0.0 |
Diagnosis, Differential | 2 | 0.0 |
Lipopolysaccharides | 2 | 1.0 |
Reproducibility of Results | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Tissue Distribution | 8 | 0.0 |
Adult | 12 | 0.0 |
Fibroblasts/metabolism | 9 | 0.0 |
Transfection | 11 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
*Apoptosis | 2 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Glutathione/metabolism | 2 | 0.0 |
Kinetics | 8 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
In Situ Hybridization | 2 | 0.0 |
Liver Neoplasms/*metabolism | 2 | 2.0 |
Mice, Inbred BALB C | 3 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
Organ Specificity | 4 | 0.0 |
Protein Binding | 14 | 0.0 |
Rats | 10 | 0.0 |
Rats, Wistar | 3 | 0.0 |
Gene Expression | 6 | 0.0 |
Mice, Transgenic | 8 | 0.0 |
Milk/*chemistry | 4 | 26.0 |
English Abstract | 11 | 0.0 |
Middle Aged | 11 | 0.0 |
Fetus | 2 | 0.0 |
Iodine Radioisotopes | 4 | 1.0 |
Lactoferrin/*metabolism | 15 | 75.0 |
Binding Sites | 18 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Iron/chemistry | 2 | 13.0 |
Infant, Newborn | 5 | 0.0 |
*Milk, Human | 2 | 15.0 |
Cell Line, Tumor | 7 | 0.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Microbial Sensitivity Tests | 4 | 1.0 |
Models, Molecular | 6 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Apoptosis | 3 | 0.0 |
DNA, Complementary | 6 | 0.0 |
*Leucine Zippers | 2 | 4.0 |
Nuclear Proteins/genetics/metabolism | 2 | 1.0 |
Oncogene Proteins, Fusion/genetics/*metabolism | 2 | 5.0 |
Trans-Activators/genetics/*metabolism | 4 | 1.0 |
Transcription Factors/*genetics | 3 | 0.0 |
Carbazoles/pharmacology | 2 | 4.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
Fibroblasts/drug effects/*physiology | 2 | 16.0 |
Indoles/pharmacology | 2 | 0.0 |
Lung/cytology | 4 | 6.0 |
Phenotype | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Gene Expression Regulation | 6 | 0.0 |
RNA, Messenger/metabolism | 8 | 0.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Transcription Factors/genetics/metabolism | 3 | 0.0 |
Drug Stability | 2 | 0.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Ligands | 2 | 0.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Thiazoles/*pharmacology | 2 | 3.0 |
Anti-Bacterial Agents/*diagnostic use | 2 | 66.0 |
Bacterial Infections/*radionuclide imaging | 2 | 66.0 |
Rabbits | 3 | 0.0 |
Technetium/*diagnostic use | 3 | 12.0 |
Blotting, Northern | 6 | 0.0 |
Blotting, Western | 11 | 0.0 |
Dimerization | 6 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Leucine Zippers | 9 | 5.0 |
Liver/metabolism | 5 | 0.0 |
*Membrane Proteins | 3 | 0.0 |
Models, Biological | 2 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Protein Structure, Tertiary | 7 | 0.0 |
Time Factors | 8 | 0.0 |
Transcription, Genetic | 7 | 0.0 |
*DNA-(Apurinic or Apyrimidinic Site) Lyase | 3 | 7.0 |
Oxidation-Reduction | 4 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
Milk, Human | 2 | 18.0 |
3T3 Cells | 3 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Sequence Homology, Amino Acid | 7 | 0.0 |
Cell Membrane Permeability/drug effects | 2 | 3.0 |
Drug Resistance, Microbial | 2 | 1.0 |
Aged | 6 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Receptors, Transforming Growth Factor beta/genetics/*metabolism | 2 | 22.0 |
Antigens, CD14/*metabolism | 2 | 2.0 |
Lipopolysaccharides/*metabolism | 6 | 4.0 |
Protein Conformation | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 10 | 0.0 |
Hydrogen Peroxide/metabolism | 2 | 1.0 |
Lactoferrin/*chemistry/*metabolism | 2 | 50.0 |
Immunoblotting | 5 | 0.0 |
Plants, Genetically Modified | 3 | 13.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
Carrier Proteins/isolation & purification/*metabolism | 2 | 6.0 |
Chromatography, Affinity | 2 | 0.0 |
Ribosomal Proteins/*diagnostic use | 2 | 100.0 |
Escherichia coli | 2 | 0.0 |
DNA/*metabolism | 4 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Hela Cells | 2 | 0.0 |
Helix-Loop-Helix Motifs | 3 | 1.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 2 | 0.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Iron/metabolism | 8 | 6.0 |
Pregnancy | 3 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Lung/cytology/*metabolism | 5 | 15.0 |
Adolescent | 3 | 0.0 |
Child, Preschool | 2 | 0.0 |
Infant | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Caseins/genetics | 2 | 18.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Gene Expression Regulation/*genetics | 2 | 1.0 |
Lactoferrin/*biosynthesis/*genetics | 3 | 75.0 |
Binding, Competitive | 8 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Apoptosis/*genetics | 2 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
*Trans-Activation (Genetics) | 3 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Crystallography, X-Ray | 3 | 0.0 |
Glycosylation | 8 | 0.0 |
Lactoferrin/*chemistry | 3 | 100.0 |
Chromosome Mapping | 5 | 0.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 2 | 1.0 |
Point Mutation | 2 | 0.0 |
Transcription Factors/chemistry/genetics/*metabolism | 2 | 1.0 |
Brain/metabolism | 3 | 0.0 |
*Circadian Rhythm | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Aging/*physiology | 2 | 0.0 |
Transcription Factors/*genetics/physiology | 2 | 2.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Lactoferrin/*genetics | 2 | 16.0 |
Polymorphism, Genetic | 3 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Mutagenesis | 3 | 0.0 |
Lipoproteins, HDL/*metabolism | 2 | 1.0 |
Molecular Weight | 4 | 0.0 |
Alkaloids/*pharmacology | 2 | 3.0 |
*Benzylisoquinolines | 2 | 18.0 |
Fibroblasts/cytology | 2 | 0.0 |
Lung/*cytology | 3 | 9.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Arginine/genetics/*metabolism | 2 | 20.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Trypsin/metabolism | 3 | 2.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
Promoter Regions (Genetics)/*genetics | 2 | 0.0 |
Translocation, Genetic/*genetics | 2 | 0.0 |
Cytokines/immunology | 2 | 1.0 |
Hydrogen Bonding | 2 | 1.0 |
Risk Factors | 2 | 0.0 |
Muramidase/*metabolism | 2 | 50.0 |
Carcinoma, Hepatocellular/*metabolism/*pathology | 2 | 50.0 |
Liver Neoplasms/*metabolism/*pathology | 2 | 50.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Antibody Specificity | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Radioimmunoassay | 2 | 0.0 |
DNA-Binding Proteins/biosynthesis/*metabolism | 2 | 3.0 |
Transcription Factors/biosynthesis/*metabolism | 2 | 4.0 |
DNA/metabolism | 2 | 0.0 |
Mutation | 2 | 0.0 |
*Bacterial Proteins | 3 | 1.0 |
Fibronectins/metabolism | 2 | 1.0 |
Restriction Mapping | 2 | 0.0 |
Genes, Reporter | 4 | 0.0 |
DNA-Binding Proteins/genetics/*physiology | 3 | 1.0 |
Oncogene Proteins, Fusion/genetics/*physiology | 2 | 11.0 |
Transcription Factors/genetics/*physiology | 3 | 1.0 |
Lung | 2 | 2.0 |
Plasmids | 4 | 0.0 |
Consensus Sequence | 2 | 0.0 |
Leukemia, Lymphocytic, Acute/*genetics | 3 | 3.0 |
Oligodeoxyribonucleotides | 5 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Species Specificity | 3 | 0.0 |
Collagen/*biosynthesis | 2 | 5.0 |
Kidney/metabolism | 2 | 0.0 |
Lactoferrin/*chemistry/genetics/*metabolism | 3 | 100.0 |
*Chromosomes, Human, Pair 19 | 4 | 1.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 2 | 2.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Fibronectins/*metabolism | 3 | 4.0 |
Heparan Sulfate Proteoglycan | 2 | 6.0 |
Transforming Growth Factor beta/*pharmacology | 2 | 0.0 |
*Chromosomes, Human, Pair 17 | 3 | 0.0 |
*Translocation, Genetic | 3 | 0.0 |
Trypsin | 2 | 1.0 |
Temperature | 4 | 0.0 |
Fibroblasts | 2 | 0.0 |
Blotting, Southern | 3 | 0.0 |
Cloning, Molecular/methods | 2 | 1.0 |
Radioligand Assay | 2 | 0.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 2 | 3.0 |
Disease Models, Animal | 2 | 0.0 |
Liver Neoplasms/*metabolism/pathology | 2 | 2.0 |
Neoplasm Transplantation | 2 | 0.0 |
alpha-Fetoproteins/*biosynthesis | 2 | 3.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Tretinoin/*pharmacology | 3 | 0.0 |
Phorbols/*pharmacology | 2 | 5.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
